The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer
- 1 October 2018
- journal article
- review article
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 52, 107-116
Abstract
No abstract availableKeywords
Funding Information
- ERC CoG ImmunoFIT Methusalem (G066515N)
- Flamish government FWO (G0A0818N)
- Belgian Association Against Cancer
- National Institute of Health NIH/NCI
This publication has 130 references indexed in Scilit:
- Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venulesThe Journal of Pathology, 2018
- The Multifaceted Role of Perivascular Macrophages in TumorsCancer Cell, 2016
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer TherapyCancer Cell, 2015
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating HypoxiaCancer Cell, 2014
- Escape Mechanisms from Antiangiogenic Therapy: An Immune Cell’s Perspective2013
- The angiopoietin‐2 gene of endothelial cells is up‐regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA‐2 and Ets‐1Journal of Cellular Physiology, 2008
- A Perivascular Niche for Brain Tumor Stem CellsCancer Cell, 2007
- Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsCancer Cell, 2005
- Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitorsCancer Cell, 2005
- Incidence and distribution of argininosuccinate synthetase deficiency in human cancersCancer, 2004